Stem Cell Educator therapy remains the global-leading technology for the treatment of type 1 diabetes

The Juvenile Diabetes Cure Alliance (JDCA) summarizes recent progress made during 2018 toward a practical cure for type 1 diabetes (T1D). To date, there are 518 clinical trials in T1D, registered in Only ten (10) active projects are being tested in clinical trials as “Practical Cure Projects”. Stem Cell Educator therapy, patented technology by Tianhe Stem Cell Biotechnologies, remained in the top list of these ten technologies. See JDCA annual report 2018.  

Stem Cell Educator (SCE) therapy, developed and patented by Dr. Yong Zhao at University of Illinois at Chicago, uses Cord Blood Stem Cells to “educate” autologous mononuclear cells, reversing autoimmunity in patients with T1D and providing lasting improvement of islet beta-cell function (C-peptide levels), reduced median glycated hemoglobin A1C (HbA1C) values, and decreased median daily usage of insulin. SCE has been proven safe and effective in Chinese and Caucasian subjects for the improvement of T1D and other autoimmune diseases.